Jason Barr – Team LeaderSharon Valvona – Main Client ContactMarina Stavrakantonaki – Main Customer ContactScott Junkin – Technology Specialist

Andy Dickson – MentorMichael Sapienza – Mentor

“…died of massive uncontrolled and untreated bleeding as a result of the clips' having moved out of place. “ “Haaretz”, December 2006

“a wayward spark… seared a tiny hole in her colon… malfunctioning bladder and disabling pain… 13 operations so far…prevent her from working or bearing children” New York Times, March 2006

"It wouldn't surprise me in the least if it caused more than 100 deaths and 10,000 injuries annually," Dr. Alan Johns

"Very little has changed since the first minimally- invasive surgeries in the early 1990s. The tools we use are still remarkably crude." Dr. Wayne Poll

Between 1996 and 2005, • 27 adverse events have been reported• 2 resulted in death - due to delayed postoperative bleeding. • clips apparently had been placed without issue • did not maintain control of the vessel. “Reported Failures Of The Polymer Self-Locking (Hem-O-Lok) Clip” Urology / Nephrology Feb 2007

Self-Articulating Coil TechnologySelf-Articulating Coil Technology

• Features• Compression Member

– Outer surface– Hollow– Compressed under

tension at designated areas

• Tensioning Member– Inner material– Moves within

compression member• Retainment member

– Stops movement of tensioning member

– Provides force transfer to compression members

Retaining Member

Compression Member

Tensioning Member

SolutionSolution

Market Opportunity

$10.6 Billion

3.7% = $389Million

Unique Competitive Advantage

Competition

MedtronicBoston

ScientificJohnson & Johnson

St. Jude Medical

Simplex

Annual Sales ($ mil.) 12,299.00 7,821.00 53,324.00 3,779.30 389.00

Employees38,000 28,600 122,200 12,000 250

Market Cap ($ mil.)54,678.70 18,760.10 177,883.20 14,972.10 10X?

From now until beginning of 2009 Get the Product to the Market

2009 – 2010 Prove Value in Live Surgery

2010 – 2011 Build Reputation of Excellence

2011 – 2015 Exit thru Sale

FDA Approval

MarketEntry

TacticalSuccess

Strategic SuccessMarket Penetration

Financials

(000’s) 2009 2010 2011 2012 2013 2014 2015

Revenues 4,284 9,084 19,260 40,839 86,592 183,603 389,296

Operating Expenses

6,348 8,510 15,406 29,329 56,255 111,758 224,843

Net Income (2,064) 343 2,312 6,905 18,202 43,106 98,671

Cumulative Cash Flow

(5,303) (5,383) (3,695) 2,103 18,070 56,549 145,622

Investment 5,400 Total Investment Required to Breakeven

The Team

Andy Dickson, Executive Mentor 16 years of professional experience as an investment professional. Co-founder of a frim that helps early-stage companies successfully raise

private equity.

Scott Junkin Sr. Product Engineer, Emerson

Eric Foster MS Engineering

Advisory Board TBD

Short-term Goals

• Product validation• Surgeon champions• IP negotiation• Early stage funding• Trial prototype• FDA 510K exemption

Extra Slides Formats if Needed